Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
27
ADVM Quote, Financials, Valuation and Earnings
Last price:
$4.70
Seasonality move
:
20.2%
Day range:
$4.59 - $4.83
52-week range:
$4.59 - $29.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.68x
Volume:
183.1K
Avg. volume:
272.4K
1-year change:
-40%
Market cap:
$98.6M
Revenue:
$3.6M
EPS (TTM):
-$6.01
Analysts' Opinion
-
Consensus RatingAdverum Biotechnologies has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $30.00, Adverum Biotechnologies has an estimated upside of 526.88% from its current price of $4.74.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $4.74.
Fair Value
-
According to the consensus of 7 analysts, Adverum Biotechnologies has 526.88% upside to fair value with a price target of $30.00 per share.
ADVM vs. S&P 500
-
Over the past 5 trading days, Adverum Biotechnologies has underperformed the S&P 500 by -11.42% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Adverum Biotechnologies does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Adverum Biotechnologies revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Adverum Biotechnologies reported revenues of $1M.
Earnings Growth
-
Adverum Biotechnologies has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Adverum Biotechnologies reported earnings per share of -$1.30.
Enterprise value:
-54.6M
EV / Invested capital:
-0.38x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.63x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-41.8%
Net Income Margin (TTM):
--
Return On Equity:
-69.14%
Return On Invested Capital:
-69.14%
Operating Margin:
-2922.1%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | $1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$157.6M | -$131.8M | -$103.1M | -$34.5M | -$29.2M | |
| EBITDA | -$151.5M | -$125.4M | -$99.2M | -$33M | -$28.3M | |
| Diluted EPS | -$15.70 | -$12.59 | -$6.01 | -$3.26 | -$1.30 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $459.7M | $347.8M | $213.2M | $124.6M | $161.1M | |
| Total Assets | $507.7M | $490.6M | $332.4M | $196.8M | $234.4M | |
| Current Liabilities | $16.1M | $25.3M | $28.6M | $28.9M | $27.7M | |
| Total Liabilities | $43M | $144.6M | $124M | $94.1M | $90.3M | |
| Total Equity | $464.7M | $346M | $208.3M | $102.7M | $144.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$115.4M | -$88M | -$85.5M | -$23.9M | -$21.1M | |
| Cash From Investing | $163.4M | $109M | -$47.6M | $18.2M | -$13.3M | |
| Cash From Financing | $740K | $145K | $119.9M | -$105K | -- | |
| Free Cash Flow | -$131.4M | -$88.9M | -$86.1M | -$24.4M | -$21.3M | |
ADVM
Sector
Market Cap
$98.6M
$45.6M
Price % of 52-Week High
15.96%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-40%
-31.35%
Beta (5-Year)
0.912
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$5.07
200-day SMA
Sell
Level
$8.42
Bollinger Bands (100)
Sell
Level
6.09 - 7.75
Chaikin Money Flow
Sell
Level
-91.6M
20-day SMA
Sell
Level
$5.72
Relative Strength Index (RSI14)
Sell
Level
26.02
ADX Line
Sell
Level
14.27
Williams %R
Buy
Level
-91.9355
50-day SMA
Sell
Level
$6.82
MACD (12, 26)
Sell
Level
-0.56
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
32.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-8.7354)
Sell
CA Score
(Annual)
Level (-2.5506)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (4.4889)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Stock Forecast FAQ
In the current month, ADVM has received 6 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ADVM average analyst price target in the past 3 months is $30.00.
-
Where Will Adverum Biotechnologies Stock Be In 1 Year?
According to analysts, the consensus estimate is that Adverum Biotechnologies share price will rise to $30.00 per share over the next 12 months.
-
What Do Analysts Say About Adverum Biotechnologies?
Analysts are divided on their view about Adverum Biotechnologies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Adverum Biotechnologies is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Adverum Biotechnologies's Price Target?
The price target for Adverum Biotechnologies over the next 1-year time period is forecast to be $30.00 according to 7 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ADVM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Adverum Biotechnologies is a Buy. 6 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ADVM?
You can purchase shares of Adverum Biotechnologies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Adverum Biotechnologies shares.
-
What Is The Adverum Biotechnologies Share Price Today?
Adverum Biotechnologies was last trading at $4.70 per share. This represents the most recent stock quote for Adverum Biotechnologies. Yesterday, Adverum Biotechnologies closed at $4.74 per share.
-
How To Buy Adverum Biotechnologies Stock Online?
In order to purchase Adverum Biotechnologies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
52
TSLL alert for Dec 24
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
73
PSIX alert for Dec 24
Power Solutions International [PSIX] is up 27.42% over the past day.
Sell
31
SOXL alert for Dec 24
Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.
